Corcept Therapeutics INC (CORT) — SEC Filings

Overview

Corcept Therapeutics INC (CORT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: CORCEPT THERAPEUTICS INC filed an 8-K on March 25, 2026, under Item 8.01, indicating 'Other Events.' While the filing itself doesn't detail the specific event, the inclusion of an EX-99.1 exhibit suggests a press release or other material information was disclosed. This matters to investors because

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 29 neutral. The dominant filing sentiment for Corcept Therapeutics INC is neutral.

Filing Type Overview

Corcept Therapeutics INC (CORT) has filed 14 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 DEFA14A, 6 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• CORCEPT THERAPEUTICS Files 8-K for 'Other Events' on March 25, 2026 — 8-K · Mar 25, 2026
  CORCEPT THERAPEUTICS INC filed an 8-K on March 25, 2026, under Item 8.01, indicating 'Other Events.' While the filing itself doesn't detail the specific event,
• 8-K Filing — 8-K · Dec 31, 2025
• Corcept's Profit Plunges 58% Despite Revenue Growth — 10-Q · Nov 4, 2025 Risk: high
  CORCEPT THERAPEUTICS INC (CORT) reported a significant decrease in net income for the three months ended September 30, 2025, falling to $19.668 million from $47
• Corcept Therapeutics Terminates Material Agreement — 8-K · Oct 14, 2025 Risk: medium
  Corcept Therapeutics Inc. filed an 8-K on October 14, 2025, reporting the termination of a material definitive agreement. The filing does not provide specific d
• Corcept Therapeutics Files 8-K on Officer/Director Changes — 8-K · Oct 6, 2025 Risk: medium
  On October 6, 2025, Corcept Therapeutics Incorporated filed an 8-K report. The filing indicates changes related to the departure of directors or certain officer
• Corcept Therapeutics Files 8-K — 8-K · Sep 10, 2025 Risk: low
  On September 10, 2025, Corcept Therapeutics Incorporated filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibit
• Corcept Thrives on Strong Q2 Revenue, Net Income Growth — 10-Q · Jul 31, 2025 Risk: medium
  CORCEPT THERAPEUTICS INC reported total revenues of $123.4 million for the three months ended June 30, 2025, a significant increase from $105.1 million for the
• Corcept Therapeutics Files 8-K — 8-K · Jul 14, 2025 Risk: low
  Corcept Therapeutics Inc. filed an 8-K on July 14, 2025, reporting on other events and financial statements/exhibits. The filing does not contain specific finan
• Corcept Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · Jun 16, 2025 Risk: low
  Corcept Therapeutics Incorporated filed an 8-K on June 16, 2025, reporting on matters submitted to a vote of security holders and financial statements as of Jun
• Corcept Therapeutics Files Q1 2025 10-Q — 10-Q · May 5, 2025 Risk: medium
  Corcept Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position. Key financia
• Corcept Therapeutics Executive Compensation Revealed — DEF 14A · Apr 25, 2025 Risk: low
  Corcept Therapeutics Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
• Corcept Therapeutics Files 8-K — 8-K · Mar 31, 2025 Risk: low
  Corcept Therapeutics Inc. filed an 8-K on March 31, 2025, reporting other events and financial statements. The filing does not contain specific details on new e
• Corcept Therapeutics Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Corcept Therapeutics Inc. filed an 8-K on March 3, 2025, reporting other events and financial statements/exhibits. The filing does not contain specific details
• Corcept Therapeutics Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  Corcept Therapeutics Inc. filed its 2024 10-K on February 26, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The compan
• Corcept Therapeutics Files 8-K — 8-K · Dec 30, 2024 Risk: low
  Corcept Therapeutics Inc. filed an 8-K on December 30, 2024, reporting on other events and financial statements. The filing does not contain specific financial
• Corcept Therapeutics Files Q3 2024 10-Q — 10-Q · Oct 30, 2024 Risk: medium
  Corcept Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detaili
• Corcept Therapeutics Files Q2 2024 10-Q — 10-Q · Jul 29, 2024 Risk: medium
  Corcept Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial performance and operations for the seco
• Corcept Therapeutics Announces New CMO Employment Agreement — 8-K · May 23, 2024 Risk: low
  Corcept Therapeutics Incorporated announced on May 17, 2024, that it has entered into a new employment agreement with its Chief Medical Officer, Dr. Vera. The a
• Corcept Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk: low
  CORCEPT THERAPEUTICS INC (CORT) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Corcept Therapeutics Inc. filed a 10-Q report for the period ending
• Corcept Therapeutics Files Proxy Statement Supplement — DEFA14A · Apr 18, 2024 Risk: low
  Corcept Therapeutics Inc. filed a Definitive Additional Materials proxy statement on April 18, 2024, related to its Annual Meeting of Stockholders. The filing i
• Corcept Therapeutics Enters Material Definitive Agreement — 8-K · Apr 17, 2024 Risk: medium
  Corcept Therapeutics Inc. entered into a material definitive agreement on April 12, 2024. This agreement involves a direct financial obligation or an obligation
• Corcept Therapeutics Inc. Files Definitive Proxy Statement — DEF 14A · Apr 10, 2024 Risk: low
  CORCEPT THERAPEUTICS INC (CORT) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Corcept Therapeutics Inc. filed a Definitive Proxy Statement (
• SC 13G/A Filing — SC 13G/A · Mar 27, 2024
• Corcept Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk: low
  CORCEPT THERAPEUTICS INC (CORT) filed a Annual Report (10-K) with the SEC on February 15, 2024. Corcept Therapeutics Inc. filed its annual report for the fiscal
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Belanoff Maintains 6.58M Share Stake in Corcept Therapeutics — SC 13G/A · Feb 12, 2024 Risk: low
  Joseph K. Belanoff, a key individual associated with Corcept Therapeutics Inc. (CORT), filed an SC 13G/A on February 12, 2024, updating his beneficial ownership
• BlackRock Amends Corcept Therapeutics Stake, Signals Continued Confidence — SC 13G/A · Jan 22, 2024
  BlackRock, Inc. filed an amended SC 13G/A on January 22, 2024, indicating its ownership of Common Stock in CORCEPT THERAPEUTICS INCORPORATED as of December 31,
• Corcept Therapeutics Files 8-K on Operations & Financial Condition — 8-K · Jan 8, 2024
  Corcept Therapeutics Incorporated filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as other events. This
• Corcept Therapeutics Files Routine 8-K on Jan 2, 2024 — 8-K · Jan 2, 2024
  Corcept Therapeutics Incorporated filed an 8-K on January 2, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. This filing is a routine

Risk Profile

Risk Assessment: Of CORT's 22 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Corcept Therapeutics INC's most recent 10-Q filing (Nov 4, 2025):

• Revenue: $207,638,000
• Net Income: $19,668,000
• EPS: $0.16
• Cash Position: $125,138,000
• Operating Margin: 4.9%
• Total Assets: $823,607,000

Key Executives

• Joseph K. Belanoff, M.D.
• William Guyer, Pharm.D.
• Sean Maduck
• Atabak Mokari
• Charles Robb
• William Guyer
• Dr. Vera
• Joseph K. Belanoff

Industry Context

Corcept Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing therapies for endocrine-related disorders. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight from bodies like the FDA. Success hinges on clinical trial outcomes, market access, and effective commercialization strategies.

Top Tags

8-K (5) · regulatory-filing (4) · 10-Q (4) · corporate-governance (3) · pharmaceuticals (3) · financials (3) · SEC Filing (3) · Corcept Therapeutics (3) · Cushing's Syndrome (2) · Revenue Growth (2)

Key Numbers

• Product Revenue, Net (Q3 2025): $207.6M — Increased 13.7% from $182.5M in Q3 2024
• Net Income (Q3 2025): $19.7M — Decreased 58.3% from $47.2M in Q3 2024
• Selling, General and Administrative Expenses (Q3 2025): $124.0M — Increased 68.1% from $73.7M in Q3 2024
• Research and Development Expenses (Q3 2025): $68.8M — Increased 16.0% from $59.3M in Q3 2024
• Common Stock Repurchases (9M 2025): $172.9M — Significantly up from $15.7M in 9M 2024
• Diluted Net Income Per Common Share (Q3 2025): $0.16 — Down from $0.41 in Q3 2024
• Product Revenue, Net (9M 2025): $559.3M — Increased 13.4% from $493.2M in 9M 2024
• Net Income (9M 2025): $75.4M — Decreased 31.8% from $110.5M in 9M 2024
• Selling, General and Administrative Expenses (9M 2025): $318.5M — Increased 61.7% from $196.9M in 9M 2024
• Net Cash Provided by Operating Activities (9M 2025): $103.5M — Down from $138.2M in 9M 2024
• Q2 2025 Revenue: $123.4M — Up 17.4% from Q2 2024's $105.1M
• Q2 2025 Net Income: $38.2M — Up 21.3% from Q2 2024's $31.5M
• H1 2025 Revenue: $240.1M — Up 19.3% from H1 2024's $201.3M
• H1 2025 Net Income: $72.5M — Up 20.4% from H1 2024's $60.2M
• Cash and Equivalents: $250.3M — As of June 30, 2025, indicating strong liquidity

Forward-Looking Statements

• {"claim":"Joseph K. Belanoff will maintain a significant ownership stake in Corcept Therapeutics Inc. for the foreseeable future.","entity":"Joseph K. Belanoff","targetDate":"December 31, 2024","confidence":"medium"}

Frequently Asked Questions